MX2019008458A - Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos. - Google Patents

Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos.

Info

Publication number
MX2019008458A
MX2019008458A MX2019008458A MX2019008458A MX2019008458A MX 2019008458 A MX2019008458 A MX 2019008458A MX 2019008458 A MX2019008458 A MX 2019008458A MX 2019008458 A MX2019008458 A MX 2019008458A MX 2019008458 A MX2019008458 A MX 2019008458A
Authority
MX
Mexico
Prior art keywords
protein kinase
reducing
liver regeneration
kinase inhibitors
promoting liver
Prior art date
Application number
MX2019008458A
Other languages
English (en)
Inventor
Albrecht Wolfgang
Laufer Stefan
Selig Roland
Klövekorn Phillip
Präfke Bent
Original Assignee
Heparegenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heparegenix Gmbh filed Critical Heparegenix Gmbh
Publication of MX2019008458A publication Critical patent/MX2019008458A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a MKK4 (proteina cinasa 4 activada por mitogeno) y su uso en promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos; los inhibidores de MKK4 inhiben selectivamente la proteina cinasa MKK4 sobre las proteinas cinasas JNK y MKK7.
MX2019008458A 2017-01-17 2018-01-17 Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos. MX2019008458A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17151787 2017-01-17
EP17204638 2017-11-30
PCT/EP2018/051110 WO2018134254A1 (en) 2017-01-17 2018-01-17 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Publications (1)

Publication Number Publication Date
MX2019008458A true MX2019008458A (es) 2019-12-02

Family

ID=61132397

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008458A MX2019008458A (es) 2017-01-17 2018-01-17 Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos.

Country Status (11)

Country Link
US (1) US11040027B2 (es)
EP (1) EP3571200B8 (es)
JP (1) JP7300394B2 (es)
CN (1) CN110291089B (es)
AU (1) AU2018209164B2 (es)
BR (1) BR112019014593A2 (es)
CA (1) CA3049926A1 (es)
ES (1) ES2928773T3 (es)
MX (1) MX2019008458A (es)
WO (1) WO2018134254A1 (es)
ZA (1) ZA201905078B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN111788195B (zh) 2018-01-31 2023-11-21 海帕瑞吉尼克斯股份有限公司 用于促进肝脏再生或减少或预防肝细胞死亡的蛋白激酶mkk4抑制剂
US11731968B2 (en) 2018-06-21 2023-08-22 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3104246A1 (en) * 2018-07-16 2020-01-23 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2021018820A1 (en) 2019-07-29 2021-02-04 Heparegenix Gmbh Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP4090659B1 (en) * 2020-01-15 2024-06-12 HepaRegeniX GmbH 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
CN111320548B (zh) * 2020-04-24 2022-10-18 浦拉司科技(上海)有限责任公司 抗癌药物中间体2-氟-3-氨基苯甲酸甲酯的合成方法
KR20210135092A (ko) * 2020-05-04 2021-11-12 아주대학교산학협력단 톨-유사 수용체 7/9 억제 기능이 있는 길항성 소분자 화합물
CN111517977B (zh) * 2020-05-28 2023-05-23 爱斯特(成都)生物制药股份有限公司 一种合成2,4-二氟-3-三甲基乙酰胺基苯甲酸的方法
WO2024064823A2 (en) * 2022-09-21 2024-03-28 The Regents Of The University Of California Compositions of staurosporine analogs and uses thereof

Family Cites Families (565)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
BRPI0611863B1 (pt) 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
US20130210034A1 (en) 2005-11-04 2013-08-15 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
US20070105165A1 (en) 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
US7812143B2 (en) 2006-03-31 2010-10-12 Memorial Sloan-Kettering Cancer Center Biomarkers for cancer treatment
KR20090071603A (ko) 2006-09-19 2009-07-01 노파르티스 아게 Raf 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
EP1977765A1 (en) 2007-04-03 2008-10-08 Diatos Peptide prodrugs
WO2008148522A2 (en) 2007-06-04 2008-12-11 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Method to identify modulators of b-raf protein kinase and their use for the treatment of anxiety and depression
CA2639416C (en) 2007-09-11 2019-12-31 F. Hoffmann-La Roche Ag Diagnostic test for susceptibility to b-raf kinase inhibitors
EP2294769B1 (en) 2008-07-01 2012-10-24 Telefonaktiebolaget L M Ericsson (PUBL) Methods and apparatus using precoding matrices in a mimo telecommunications system
CA2729914A1 (en) 2008-07-11 2010-01-14 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
WO2010056662A1 (en) 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
CN102421776A (zh) 2009-03-11 2012-04-18 普莱希科公司 抑制Raf激酶的吡咯并[2,3-b]吡啶衍生物
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
AR078033A1 (es) 2009-04-03 2011-10-12 Plexxikon Inc Una dispersion solida, que contiene al compuesto {3-[5-(4-(cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico, composiciones y formulaciones que comprenden a dicha dispersion solida; metodos para fabricar dicha dispersion solida, formas 1 y 2 de
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EP2461835A4 (en) 2009-08-07 2013-05-15 Wistar Inst COMPOSITIONS WITH JARID1B INHIBITORS AND METHOD FOR THE TREATMENT OF CANCER
EP2467491A4 (en) 2009-08-21 2014-04-02 Sinai School Medicine METHODS OF USING CD44 FUSION PROTEINS TO TREAT CANCER
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
WO2011079133A2 (en) 2009-12-23 2011-06-30 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2011097594A2 (en) 2010-02-08 2011-08-11 Kinagen, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
ES2714875T3 (es) 2010-03-09 2019-05-30 Dana Farber Cancer Inst Inc Métodos de diagnóstico y tratamiento del cáncer en pacientes que presentan o desarrollan resistencia a una primera terapia del cáncer
ES2677356T3 (es) 2010-03-24 2018-08-01 Amitech Therapeutics Solutions, Inc. Compuestos heterocíclicos útiles para la inhibición de quinasas
EA028080B1 (ru) 2010-06-09 2017-10-31 Дана-Фарбер Кэнсер Инститьют, Инк. Мутация в mek1, придающая устойчивость к ингибиторам raf и mek
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
US8779150B2 (en) 2010-07-21 2014-07-15 Hoffmann-La Roche Inc. Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
US8980549B2 (en) 2010-08-01 2015-03-17 Ramot At Tel Aviv University Ltd. MicroRNA patterns for the diagnosis, prognosis and treatment of melanoma
WO2012021778A2 (en) 2010-08-12 2012-02-16 The Regents Of The University Of California Methods for blocking cell proliferation and treating diseases and conditions responsive to cell growth inhibition
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
WO2012027536A1 (en) 2010-08-26 2012-03-01 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
WO2012027716A1 (en) 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
WO2012030738A2 (en) 2010-08-30 2012-03-08 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
US9089570B2 (en) 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US20120208837A1 (en) 2010-09-13 2012-08-16 Roger Tung Substituted azaindoles
US20120064135A1 (en) 2010-09-15 2012-03-15 Norac Pharma Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof
US9297812B2 (en) 2010-09-30 2016-03-29 Deutsches Krebsforschungzentrum Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E
US20120095078A1 (en) 2010-10-07 2012-04-19 Sanford-Burnham Medical Research Institute Methods of diagnosis and treatment of melanoma
US20120108457A1 (en) 2010-10-11 2012-05-03 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
US20120276122A1 (en) 2010-11-01 2012-11-01 Sanford-Burnham Medical Research Institute Methods for diagnosis and treatment of cellular proliferative disorders
EP2640860A4 (en) 2010-11-19 2014-06-04 Univ California COMPOSITIONS AND METHODS FOR DETECTING AND TREATING B-RAF HEMMER RESISTANT MELANOMES
CN104689318A (zh) 2010-11-19 2015-06-10 葛兰素史密斯克莱知识产权(第2号)有限公司 使用braf抑制剂的治疗方法
EP2643699A4 (en) 2010-11-22 2014-05-28 Univ Nova Southeastern ONCOLYTIC VSV MODULATION AND UPGRADING OF RAE1 AND NUP98 WITH STATINS
US9296811B2 (en) 2010-12-02 2016-03-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods for treating a tumor using an antibody that specifically binds HMW-MAA
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
MA34948B1 (fr) 2011-02-07 2014-03-01 Plexxikon Inc Composes et procedes de modulation de kinase, et leurs indications
EP2672963A4 (en) 2011-02-08 2015-06-24 Childrens Medical Center METHOD FOR THE TREATMENT OF MELANOMA
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
WO2012117396A1 (en) 2011-03-01 2012-09-07 Novotyr Therapeutics Ltd Tyrphostin derivative in combination with cytotoxic compounds for treating cancer
WO2012119095A1 (en) 2011-03-02 2012-09-07 Board Of Regents, The University Of Texas System Fus1/tusc2 therapies
JP6322413B2 (ja) 2011-03-10 2018-05-09 プロヴェクタス ファーマテック,インク. 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ
CN103857395A (zh) 2011-04-01 2014-06-11 基因泰克公司 Akt抑制剂化合物和阿比特龙的组合及使用方法
EP2694677A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
US8680066B2 (en) 2011-04-05 2014-03-25 The United States of America as represented by the Development of Veterans Affairs Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject
WO2012138809A1 (en) 2011-04-05 2012-10-11 Dawei Zhang Heterocyclic compounds as kinase inhibitors
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
EP2694504A4 (en) 2011-04-08 2014-08-27 Afraxis Holdings Inc 8-ETHYL-6 (ARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF DISEASES AFFECTING THE NERVOUS SYSTEM AND FOR THE TREATMENT OF CANCER
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
GB201107197D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Compounds
US9592236B2 (en) 2011-04-28 2017-03-14 Duke University Methods of treating hemoglobinopathies
GB201107176D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Pyrrolnitrin derivatives
EP2702054B1 (en) 2011-04-29 2018-10-24 The Trustees of The University of Pennsylvania Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
WO2012154858A1 (en) 2011-05-09 2012-11-15 Whitehead Institute For Biomedical Research Chaperone interaction assays and uses thereof
AU2012253525B2 (en) 2011-05-10 2016-09-22 Brunangelo Falini Hairy cell leukemia biomarkers and methods of using same
US20140127316A1 (en) 2011-05-20 2014-05-08 New York University Propolis and caffeic acid phenethyl ester and uses thereof
US9481910B2 (en) 2011-05-25 2016-11-01 Memorial Sloan-Kettering Cancer Center Methods and compositions for the detection of drug resistant BRAF isoforms
WO2012166949A1 (en) 2011-05-31 2012-12-06 Regents Of The University Of Minnesota Silicate prodrugs and nanoparticles
EP3446714B1 (en) 2011-06-02 2021-03-31 University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
EP3326616B1 (en) 2011-06-03 2021-07-28 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
CA2838387A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
CA2838736A1 (en) 2011-06-07 2012-12-13 Caris Mpi, Inc. Molecular profiling for cancer
US20120321637A1 (en) 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
US20140348819A1 (en) 2011-06-24 2014-11-27 Dana-Farber Cancer Institute, Inc. Methods of Treating Cancer
EP2570127A1 (en) 2011-09-16 2013-03-20 Sanofi Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
CN103930111A (zh) 2011-09-19 2014-07-16 霍夫曼-拉罗奇有限公司 包含c-met拮抗剂和b-raf拮抗剂的组合治疗
WO2013044169A1 (en) 2011-09-21 2013-03-28 Nestec S.A. Methods for determining combination therapy with il-2 for the treatment of cancer
WO2013052608A1 (en) 2011-10-07 2013-04-11 Sanford-Burnham Medical Research Institute Optically pure apogossypolone derivatives as pan-active inhibitors of anti-apoptotic bcl-2 family proteins
MX2014004991A (es) 2011-10-28 2014-05-22 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma.
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
GB201121869D0 (en) 2011-11-17 2012-02-01 Clarient Inc Method of allele-specific amplification
US9284337B2 (en) 2011-11-22 2016-03-15 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
CN104080461A (zh) 2011-11-30 2014-10-01 雪松-西奈医学中心 靶向微小rna mir-409-5p、mir-379和mir-154*来治疗前列腺癌骨转移和耐药性肺癌
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2788378A4 (en) 2011-12-09 2015-09-09 Oncomed Pharm Inc ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
EP2802314B1 (en) 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2013116228A1 (en) 2012-01-31 2013-08-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds and methods for inhibition of ap endonuclease-1/ redox factor-1 (hape1) activity
CN104185681A (zh) 2012-02-01 2014-12-03 卡姆普根有限公司 C1orf32抗体及其用于治疗癌症的用途
WO2013123463A1 (en) 2012-02-15 2013-08-22 The Translational Genomics Research Institute A system and method of genomic profiling
EP2817004B1 (en) 2012-02-22 2018-04-11 The Regents of The University of Colorado, A Body Corporate Bouvardin derivatives and therapeutic uses thereof
EP2820041B1 (en) 2012-03-02 2017-06-14 Ludwig Institute For Cancer Research Ltd. Iaspp phosphorylation and metastatic potential
EP2822926A4 (en) 2012-03-07 2015-11-04 H Lee Moffitt Cancer Ct & Res SELECTIVE HISTON DEACTY LASE-6 HEMMER
EP2823307A4 (en) 2012-03-08 2015-07-29 Bioscale Inc METHOD AND KITS FOR ANALYZING BIOMARKERS IN A SIGNAL TRANSDUCTION PATH
AU2013201584A1 (en) 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
WO2013138210A1 (en) 2012-03-14 2013-09-19 Ning Xi Substituted cyclic compounds and methods of use
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
KR101497972B1 (ko) 2012-03-21 2015-03-03 서울대학교산학협력단 Nod2 신호전달 경로를 표적으로 하는 패혈증 치료제 스크리닝 방법 및 패혈증 치료제
US9464326B2 (en) 2012-03-22 2016-10-11 University Of Maryland, Baltimore Total and phosphorylated IL-1 receptor-associated kinase-1 and IL-1 receptor-associated kinase-4 as a biomarker for cancer progression and chemotherapy resistance
BR112014023496A2 (pt) 2012-03-28 2017-07-18 Dana Farber Cancer Inst Inc mutantes c-raf que conferem resistência a inibidores de raf
WO2013148537A1 (en) 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
AU2013240191B2 (en) 2012-03-29 2018-02-22 Altor Bioscience Corporation Methods for treating neoplasia
WO2013152034A1 (en) 2012-04-02 2013-10-10 Merrimack Pharmaceuticals, Inc. Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
US20130288980A1 (en) 2012-04-02 2013-10-31 Buck Institute For Research On Aging Targeting senescent and cancer cells for selective killing by interference with foxo4
US20130288981A1 (en) 2012-04-02 2013-10-31 Buck Institute For Research On Aging Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
WO2013155077A1 (en) 2012-04-09 2013-10-17 Board Of Regents,The University Of Texas System Response markers for src inhibitor therapies
WO2013165320A1 (en) 2012-05-04 2013-11-07 Agency For Science, Technology And Research Treating cancer by increasing expression of socs6
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
KR20150006477A (ko) 2012-05-09 2015-01-16 그래댈리스, 인코포레이티드 단일-뉴클레오타이드 kras 돌연변이에 특이적인 이-기능성 짧은-헤어핀 rna (bi-shrna)
WO2013170159A1 (en) 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
US20150126621A1 (en) 2012-05-15 2015-05-07 New York University METHOD FOR PREDICTING RECURRENCE OF MELANOMA USING miRNA ALTERATIONS
WO2013171753A1 (en) 2012-05-16 2013-11-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of treating and diagnosing diseases using agents that regulate the alternative splicing pathway
WO2013173644A2 (en) 2012-05-16 2013-11-21 John Wayne Cancer Institute Immunological markers for adjuvant therapy in melanoma
WO2013177092A1 (en) 2012-05-23 2013-11-28 Sunshine Lake Pharma Co., Ltd. Substituted alkynyl pyridine compounds and methods of use
WO2013180949A1 (en) 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US20130330761A1 (en) 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
US20130336889A1 (en) 2012-06-14 2013-12-19 National Taiwan University Nanoparticle and method for detecting or treating a tumor using the same
US9220695B2 (en) 2012-06-29 2015-12-29 The Research Foundation For The State University Of New York Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances
EP2869824B1 (en) 2012-07-03 2024-03-27 Fondazione Centro San Raffaele 2-deoxyglucose for use in the treatment of autosomal dominant polycystic kidney disease or polycystic liver disease
JP2015522037A (ja) 2012-07-03 2015-08-03 ラシオファルム ゲーエムベーハー ベムラフェニブコリン塩の固体形態
WO2014009319A1 (en) 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
WO2014009318A1 (en) 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
GB201212586D0 (en) 2012-07-16 2012-08-29 Univ Murcia Cancer treatment
MX2015001194A (es) 2012-07-27 2015-11-23 Izumi Technology Llc Composiciones inhibidoras de eflujo y metodos de tratamiento que usan las mismas.
WO2014018862A1 (en) 2012-07-27 2014-01-30 Corning Incorporated Pharmaceutical compositions comprising a heat shock protein inhibitor and a|purine de novo synthesis inhibitor for treating rheumatoid arthritis or cancer
WO2014022116A2 (en) 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
WO2014022128A1 (en) 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use
CA2918608A1 (en) 2012-08-03 2014-02-06 Icahn School Of Medicine At Mount Sinai Biomarker associated with risk of melanoma reoccurrence
WO2014028461A2 (en) 2012-08-13 2014-02-20 The Rockefeller University Treatment and diagnosis of melanoma
US20140045883A1 (en) 2012-08-13 2014-02-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Ack1 kinase inhibition to treat triple negative breast cancer
BR112015003418A2 (pt) 2012-08-17 2017-07-04 Hoffmann La Roche produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica.
WO2014031856A1 (en) 2012-08-23 2014-02-27 Onconthyreon Inc. Combination therapy using pi3 kinase and braf inhibitors
TWI601725B (zh) 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
US9561266B2 (en) 2012-08-31 2017-02-07 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
US9561245B2 (en) 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
CA2885230C (en) 2012-09-19 2021-08-03 Anthony Letai Dynamic bh3 profiling
CA2886397A1 (en) 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
CN103172744B (zh) 2012-09-28 2016-01-13 武汉纽斯特生物技术有限公司 特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用
CA2887058C (en) 2012-10-03 2022-02-22 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
AU2013326463B2 (en) 2012-10-04 2018-01-18 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
EA028605B1 (ru) 2012-10-08 2017-12-29 Атрива Терапьютикс Гмбх Комбинация озельтамивира и ингибитора mek для лечения вирусных заболеваний
EP2906712A1 (en) 2012-10-10 2015-08-19 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Methods and means for predicting resistance to anti-cancer treatment
CN104994861B (zh) 2012-10-18 2019-10-11 西澳大学 使用miRNA的癌症疗法
WO2014072357A1 (en) 2012-11-06 2014-05-15 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
RU2015121367A (ru) 2012-11-08 2017-01-10 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний
US20140147411A1 (en) 2012-11-14 2014-05-29 U.S. GOVERNMENT represented by the UNITED STATES DEPARTMENT OF VETERANS AFFAIRS Methods of treating cancer and testing mutation zygosity related thereto
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲pi3激酶調節劑的芳雜環化合物及其使用方法和用途
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US20150290235A1 (en) 2012-11-23 2015-10-15 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2014089280A1 (en) 2012-12-07 2014-06-12 Calitor Sciences, Llc Alkynyl compounds and methods of use
WO2014089324A1 (en) 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use
US9945863B2 (en) 2012-12-14 2018-04-17 The Research Foundation Of State University Of New York Coiled coil helix cristae morphology 1 (CHCM1) tumor marker and cancer therapeutic target
RU2705556C2 (ru) 2012-12-21 2019-11-07 Келверум Инк. Нереплицируемые происходящие от вирусов частицы и их применение
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
CN107236816A (zh) 2012-12-27 2017-10-10 奎斯特诊断投资股份有限公司 Ddr2突变作为黑素瘤或基底细胞癌的可靶向的特征
US20150352086A1 (en) 2013-01-07 2015-12-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Heat shock protein (hsp) inhibition and monitoring effectiveness thereof
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
AU2014207311A1 (en) 2013-01-19 2015-08-20 New York University Oligooxopiperazines for p53 reactivation
EP2964245A4 (en) 2013-01-19 2016-09-21 Univ New York PEPTIDES AND PEPTIDOMIMETIC HYDROGEN-LINKED SUBSTITUTE FOR REACTIVATION OF P53
AU2014219256B2 (en) 2013-02-21 2017-02-16 Sunshine Lake Pharma Co., Ltd. Heteroaromatic compounds as PI3 kinase modulators
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
US20140243211A1 (en) 2013-02-28 2014-08-28 Indiana University Research & Technology Corporation Blood biomarkers for suicidality
CN109568312A (zh) 2013-03-05 2019-04-05 田纳西大学研究基金会 用于治疗癌症的化合物
US9937161B2 (en) 2013-03-06 2018-04-10 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
BR112015022545A2 (pt) 2013-03-13 2017-07-18 Constellation Pharmaceuticals Inc compostos de pirazolo e os usos disso
WO2015073072A1 (en) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
PL2968294T3 (pl) 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
BR112015023190A2 (pt) 2013-03-14 2017-07-18 Univ Florida regulação de câncer com o uso de compostos e/ou dieta naturais
WO2014160358A1 (en) 2013-03-14 2014-10-02 Thomas Cooper Woods Use of mir-221 and 222 lowering agents to prevent cardiovascular disease in diabetic subjects
CA2900951A1 (en) 2013-03-14 2014-10-02 Ratiopharm Gmbh Solid state forms of vemurafenib hydrochloride
WO2014145254A2 (en) 2013-03-15 2014-09-18 Sutter West Bay Hospitals Falz for use as a target for therapies to treat cancer
JP2016520528A (ja) 2013-03-15 2016-07-14 ジェネンテック, インコーポレイテッド 癌の治療及び抗癌剤耐性の防止方法
US20150018296A1 (en) 2013-03-15 2015-01-15 Golden Biotechnology Corporation Therapeutic methods and compositions utilizing cyclohexenone compounds
CA2904770A1 (en) 2013-03-15 2014-09-18 Sanofi Anti-tumoral composition comprising a pi3kbeta inhibitor and a raf inhibitor, to overcome cancer cells resistance
EP2971057A4 (en) 2013-03-15 2016-11-02 Kiyatec Inc BIOREACTOR SYSTEM
EP3434788B1 (en) 2013-03-15 2023-08-23 Life Technologies Corporation Classification and actionability indices for lung cancer
WO2014147611A1 (en) 2013-03-18 2014-09-25 Genoscience Pharma Quinolines derivatives as novel anticancer agents
US20160058751A1 (en) 2013-03-28 2016-03-03 Cellworks Group, Inc. Composition and method for treating cancer
US10220091B2 (en) 2013-04-04 2019-03-05 The General Hospital Corporation Combination treatments with sonic hedgehog inhibitors
KR20150141971A (ko) 2013-04-08 2015-12-21 파마싸이클릭스 엘엘씨 이브루티닙 병용 요법
WO2014168721A2 (en) 2013-04-12 2014-10-16 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
AU2014253040A1 (en) 2013-04-13 2015-11-05 Universidade De Coimbra Platform for targeted delivery to stem cells and tumor cells and uses thereof
WO2014172046A2 (en) 2013-04-17 2014-10-23 Life Technologies Corporation Gene fusions and gene variants associated with cancer
US9556191B2 (en) 2013-04-28 2017-01-31 Sunshine Lake Pharma Co., Ltd. Aminoquinazoline derivatives and their salts and methods of use thereof
WO2014177915A1 (en) 2013-05-01 2014-11-06 Piramal Enterprises Limited Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
US20140335077A1 (en) 2013-05-07 2014-11-13 Leonard Girnita Compositions and Methods for the Treatment of Cancer Using IGF-IR Antagonists and MAPK/ERK Inhibitors
US20160101106A1 (en) 2013-05-07 2016-04-14 Inhibikase Therapeutics, Inc. Methods for treating hcv infection
WO2014184211A1 (en) 2013-05-13 2014-11-20 Institut Gustave Roussy Prognosis and predictive biomarkers and biological applications thereof
WO2014193647A2 (en) 2013-05-26 2014-12-04 Calitor Sciences, Llc Alkenyl compounds and methods of use
SG11201509338QA (en) 2013-05-30 2015-12-30 Plexxikon Inc Compounds for kinase modulation, and indications therefor
WO2014204856A1 (en) 2013-06-17 2014-12-24 Catabasis Pharmaceuticals, Inc. Fatty acid anticancer derivatives and their uses
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
US9636328B2 (en) 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
BR112015031073B1 (pt) 2013-06-21 2022-11-29 Zenith Epigenetics Ltd Compostos inibidores bicíclicos de bromodomínio e composição farmacêutica contendo os referidos compostos
TWI680760B (zh) 2013-07-12 2020-01-01 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合
US9751832B2 (en) 2013-07-30 2017-09-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
WO2015017729A1 (en) 2013-07-31 2015-02-05 Virginia Tech Intellectual Properties, Inc. Dielectrophoresis methods for determining a property of a plurality of cancer cells
US20160166637A1 (en) 2013-08-02 2016-06-16 Virginia Tech Intellectual Properties, Inc. Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
US20150056195A1 (en) 2013-08-23 2015-02-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
CN104415335A (zh) 2013-09-02 2015-03-18 北京中康万达医药科技有限公司 体内个体化系统免疫治疗方法和装置
WO2015034519A1 (en) 2013-09-03 2015-03-12 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
WO2015034729A1 (en) 2013-09-05 2015-03-12 Calitor Sciences, Llc Substituted pyridine compounds and methods of use
WO2015038649A1 (en) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3043819A4 (en) 2013-09-11 2017-04-05 Compugen Ltd. Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
NZ718821A (en) 2013-09-11 2022-07-01 Medimmune Ltd Anti-b7-h1 antibodies for treating tumors
WO2015036643A2 (es) 2013-09-13 2015-03-19 Sierra Jiménez Angels Marcador para predecir metástasis del cancer de mama
US11680297B2 (en) 2013-09-16 2023-06-20 The Johns Hopkins University Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US20150086509A1 (en) 2013-09-25 2015-03-26 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating cancer using interferon and mapk pathway inhibitor
CN104513252B (zh) 2013-09-26 2017-11-10 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
JP6527508B2 (ja) 2013-10-01 2019-06-05 メディミューン リミテッド αVβ6を過剰発現する癌を治療及び診断する方法
EP3052103A1 (en) 2013-10-04 2016-08-10 AB Science Method for determining the prognosis of pancreatic cancer
WO2015058056A1 (en) 2013-10-18 2015-04-23 The General Hospital Corporation N-methyl pyrazoloanthrone for treatment of cancer
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US9724657B2 (en) 2013-10-22 2017-08-08 Tyme, Inc. High-speed centrifugal mixing devices and methods of use
WO2015066452A2 (en) 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating pediatric cancers
WO2015066439A2 (en) 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating hematological malignancies
KR20160070188A (ko) 2013-11-07 2016-06-17 데시페라 파마슈티칼스, 엘엘씨. 암치료에 유용한 tie2 키나아제의 억제 방법
JP6637884B2 (ja) 2013-11-08 2020-01-29 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ブロモドメインおよびエクストラターミナル(bet)タンパク質インヒビターを使用するがんのための併用療法
WO2015070224A2 (en) 2013-11-11 2015-05-14 Amgen Inc. Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
BR112016010716A8 (pt) 2013-11-13 2020-04-22 Novartis Ag dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina
WO2015070280A1 (en) 2013-11-14 2015-05-21 Newsouth Innovations Pty Limited Senescence and senescence associated secretory phenotype
WO2015080867A1 (en) 2013-11-15 2015-06-04 New York University Method for predicting development of melanoma brain metastasis
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
CN110669047A (zh) 2013-11-15 2020-01-10 昂克希尔迪克斯有限公司 用于治疗癌症的化合物、其组合物及应用方法
WO2015075749A1 (en) 2013-11-22 2015-05-28 Laurus Labs Private Limited Novel processes for the preparation of vemurafenib
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
CZ2013943A3 (cs) 2013-11-27 2015-06-03 Zentiva, K.S. Krystalické formy vemurafenibu
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
US20170000784A1 (en) 2013-12-08 2017-01-05 Van Andel Research Institute Autophagy Inhibitors
WO2015089380A2 (en) 2013-12-12 2015-06-18 Celcuity Llc Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
US20160319368A1 (en) 2013-12-17 2016-11-03 Csir A Method for Identification of Anti-HIV Human miRNA Mimics and miRNA Inhibitors and Anti-HIV Pharmaceutical Compounds
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
CA3168002A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
EP3083583B1 (en) 2013-12-20 2020-11-18 Sagimet Biosciences Inc. Heterocyclic modulators of lipid synthesis and combinations thereof
US20160339023A1 (en) 2013-12-23 2016-11-24 Fang Li Pharmaceutical Combinations
TW201609805A (zh) 2013-12-23 2016-03-16 美國禮來大藥廠 結合egfr及met之多功能抗體
JP6584322B2 (ja) 2013-12-27 2019-10-02 国立大学法人 東京医科歯科大学 アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
WO2015101996A1 (en) 2014-01-02 2015-07-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells
NZ721780A (en) 2014-01-07 2022-01-28 Sagimet Biosciences Inc Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
WO2015104292A2 (en) 2014-01-07 2015-07-16 Biomedical Research Foundation Of The Academy Of Athens Compounds for use in treating or preventing cancerous diseases
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
US20170175197A1 (en) 2014-01-29 2017-06-22 Caris Mpi, Inc. Molecular profiling of immune modulators
EP3102190A4 (en) 2014-02-07 2017-09-06 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
IN2014MU00495A (es) 2014-02-12 2015-09-25 Cipla Ltd
US20150231069A1 (en) 2014-02-20 2015-08-20 Pankaj Modi Oral formulations of chemotherapeutic agents
CA2975829A1 (en) 2014-02-20 2015-09-03 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-dll3 항체 및 약물 접합체
WO2015130922A2 (en) 2014-02-26 2015-09-03 The Trustees Of The University Of Pennsylvania Small molecule hsp70 inhibitors
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
US20150269307A1 (en) 2014-03-18 2015-09-24 Texas Tech University System Target inhibition map system for combination therapy design and methods of using same
EP3122355A4 (en) 2014-03-26 2017-08-09 The Brigham and Women's Hospital, Inc. Compositions and methods for inhibiting bmp
EP3122354B1 (en) 2014-03-28 2022-06-15 Universita' degli Studi di Genova Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
WO2015153657A2 (en) 2014-04-01 2015-10-08 Texas Tech University System Overcoming chemotherapeutic agent resistance in cancer by inhibiting mcl-1
US20170165240A1 (en) 2014-04-01 2017-06-15 Université Libre de Bruxelles New strategies for treating melanoma
WO2015153978A1 (en) 2014-04-04 2015-10-08 The University Of North Carolina At Chapel Hill Methods for the treatment of tumors
US10016421B2 (en) 2014-04-05 2018-07-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination
US10233170B2 (en) 2014-04-08 2019-03-19 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use
CA2945129A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrrolopyrimidine compounds
WO2015161230A1 (en) 2014-04-19 2015-10-22 Massachusetts Institute Of Technology Methods of reducing kinase inhibitor resistance
JP6500037B2 (ja) 2014-04-22 2019-04-10 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc 二環式ピラゾロン化合物および使用方法
EP3137117A4 (en) 2014-05-02 2018-04-04 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondria for cancer therapy
CN106535900A (zh) 2014-05-06 2017-03-22 加利福尼亚大学董事会 使用braf抑制剂的伤口愈合
BR122023025321A2 (pt) 2014-05-13 2024-02-20 Medimmune Limited Uso de anticorpos anti-b7-h1 e anti-ctla-4
WO2015175965A1 (en) 2014-05-15 2015-11-19 The Research Foundation For Suny Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof
JP6818676B2 (ja) 2014-05-16 2021-01-20 アトリバ セラピューティクス ゲーエムベーハー インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2015179075A1 (en) 2014-05-21 2015-11-26 The Board Of Regents Of The University Of Texas System Treatment for melanoma
US20170189357A1 (en) 2014-05-23 2017-07-06 Duke University Methods of limiting morbidity in hemoglobinopathies
WO2015187512A1 (en) 2014-06-01 2015-12-10 Trovagene, Inc. Monitoring treatment of histiocytosis with vemurafenib and dabrafenib
US20170079979A1 (en) 2014-06-02 2017-03-23 Children's Hospital Medical Center Therapy for solid tumors
WO2015187499A1 (en) 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
JP2017516813A (ja) 2014-06-03 2017-06-22 サインパス ファルマ, インク.Signpath Pharma, Inc. チャネル病を引き起こす薬物に対するdmpc、dmpg、dmpc/dmpg、egpg、lysopg及びlysopcの防御効果
EP3151829B1 (en) 2014-06-07 2019-10-02 Academia Sinica Novel sesquiterpene derivatives and their use in inflammation and cancer treatment
US10758526B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
US11034757B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
JP2017517558A (ja) 2014-06-13 2017-06-29 ジェネンテック, インコーポレイテッド 癌薬剤耐性の治療方法及び防止方法
WO2015193702A1 (en) 2014-06-17 2015-12-23 Bionsil S.R.L. In Liquidazione Methods for determining the sensitivity or resistance of cancer cells to at least one anticancer drug and/or therapeutically active molecule
MX2016016667A (es) 2014-06-23 2017-08-21 Genentech Inc Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.
WO2016001830A1 (en) 2014-07-01 2016-01-07 Friedrich Miescher Institute For Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US9994577B2 (en) 2014-07-04 2018-06-12 Merck Patent Gmbh Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity
US10166304B2 (en) 2014-07-11 2019-01-01 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
AU2015286569B2 (en) 2014-07-11 2021-04-15 Genmab A/S Antibodies binding AXL
WO2016008853A1 (en) 2014-07-14 2016-01-21 Universität Zürich Prorektorat Mnw Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor
CN106573060A (zh) 2014-07-15 2017-04-19 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
HUE046008T2 (hu) 2014-07-17 2020-02-28 Sunshine Lake Pharma Co Ltd I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
RU2704811C2 (ru) 2014-07-17 2019-10-31 БайоКьюрити Фармасьютикалз Инк. Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
US20180064765A1 (en) 2014-07-18 2018-03-08 Advaxis, Inc. Listeria-based immunogenic compositions for eliciting anti-tumor responses
US10550439B2 (en) 2014-07-21 2020-02-04 Novellusdx Ltd. Methods for determining drug response of patient specific mutations
CN105294655B (zh) 2014-07-26 2019-03-15 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
JP6631616B2 (ja) 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド CDK阻害剤としての2−アミノ−ピリド[2,3−d]ピリミジン−7(8H)−オン誘導体及びその使用
PT107846B (pt) 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
EP3177595B1 (en) 2014-08-08 2021-02-24 The Trustees Of The University Of Pennsylvania Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
EP3181136B1 (en) 2014-08-11 2019-11-27 The University of Tokyo Micelle containing epirubicin-complexed block copolymer and anti-cancer agent, and pharmaceutical composition containing said micelle applicable to treatment of cancer, resistant cancer or metastatic cancer
WO2016025648A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a raf inhibitor and related methods
WO2016025651A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a tor inhibitor and related methods
WO2016025650A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016030455A1 (en) 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
CN107074824B (zh) 2014-09-05 2021-01-08 基因泰克公司 作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物
EP3191128A4 (en) 2014-09-11 2018-03-14 Celldex Therapeutics, Inc. Uses of anti-her3 antibodies for treating cancer
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
AP2017009771A0 (en) 2014-10-06 2017-02-28 Mayo Foundation Carrier-antibody compositions and methods of making and using the same
EP3204360B1 (en) 2014-10-10 2020-08-26 Genentech, Inc. Therapeutic compounds and uses thereof
JP6783230B2 (ja) 2014-10-10 2020-11-11 ジェネンテック, インコーポレイテッド ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
TW201625243A (zh) 2014-10-14 2016-07-16 艾克塞里克斯公司 用於治療黑素瘤之藥物組合
WO2016061231A1 (en) 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
US20170326076A1 (en) 2014-10-27 2017-11-16 Centre National De La Recherche Scientifique Panicein compounds, compositions and uses thereof
EP3212228A2 (en) 2014-10-27 2017-09-06 Ruprecht-Karls-Universität Heidelberg Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
AU2015339137A1 (en) 2014-10-31 2017-05-25 Beth Israel Deaconess Medical Center Methods of detecting BRAF in cancer
US20170333404A1 (en) 2014-11-03 2017-11-23 Dispersol Technologies, Llc Improved formulations of vemurafenib and methods of making the same
EP3954375A1 (en) 2014-11-07 2022-02-16 AI Therapeutics, Inc. Apilimod for use in the treatment of colorectal cancer
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
WO2016077375A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Bromodomain inhibitors and uses thereof
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
WO2016075333A1 (en) 2014-11-14 2016-05-19 Vib Vzw Direct and selective inhibition of mdm4 for treatment of cancer
WO2016081281A1 (en) 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use
JP6789941B2 (ja) 2014-11-21 2020-11-25 ライジェル ファーマシューティカルズ, インコーポレイテッド Tgf−ベータ阻害剤としての縮合イミダゾール誘導体
RU2572569C1 (ru) 2014-11-27 2016-01-20 Федеральное государственное бюджетное научное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" (ФГБНУ "РОНЦ им. Н.Н. Блохина") СПОСОБ ПОЛУЧЕНИЯ ПОДКОЖНЫХ КСЕНОГРАФТОВ КЛЕТОЧНОЙ ЛИНИИ МЕЛАНОМЫ КОЖИ ЧЕЛОВЕКА mel Cher С МУТАЦИЕЙ V600E BRAF ДЛЯ ДОКЛИНИЧЕСКОГО ИЗУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ТАРГЕТНЫХ СРЕДСТВ
EP3632915A1 (en) 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2016083956A1 (en) 2014-11-29 2016-06-02 Shilpa Medicare Limited Substantially pure vemurafenib and its salts
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016089208A2 (en) 2014-12-04 2016-06-09 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
US9862698B2 (en) 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
US20190125745A1 (en) 2014-12-17 2019-05-02 Rgenix, Inc. Treatment and diagnosis of cancer
WO2016097870A1 (en) 2014-12-17 2016-06-23 Zenith Epigenetics Corp. Substituted bicyclic compounds as bromodomain inhibitors
WO2016097036A1 (en) 2014-12-17 2016-06-23 Karo Bio Ab Estrogen receptor ligand for use in treating melanoma
MA41217A (fr) 2014-12-19 2017-10-24 Advaxis Inc Polythérapies ayant des souches de listeria recombinées
DE102014226903A1 (de) 2014-12-23 2016-06-23 Olympus Winter & Ibe Gmbh HF-Hilfsstoff, medizinisches System und Verfahren zum selektiven Behandeln von Krebsgewebe
TWI525110B (zh) 2014-12-24 2016-03-11 財團法人工業技術研究院 聚合物、及包含其之醫藥組合物
ES2923602T3 (es) 2014-12-31 2022-09-28 Guardant Health Inc Detección y tratamiento de enfermedades que muestran heterogeneidad celular de enfermedad y sistemas y métodos para comunicar los resultados de las pruebas
CA2972919A1 (en) 2015-01-09 2016-07-14 Gilead Apollo, Llc Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
WO2016115218A1 (en) 2015-01-14 2016-07-21 The California Institute For Biomedical Research Antibody drug conjugates for the treatment of immune conditions
WO2016115376A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Of California Detection and treatment of double drug resistant melanomas
WO2016116935A1 (en) 2015-01-21 2016-07-28 Yeda Research And Development Co. Ltd. Use of rasa2 as a prognostic and therapeutic marker for melanoma
EP3936141A3 (en) 2015-01-23 2022-03-23 Erasmus University Rotterdam Medical Center Anti-senescence compounds and uses thereof
WO2016123054A2 (en) 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
CN107530298B (zh) 2015-01-26 2021-06-04 耶鲁大学 利用酪氨酸激酶抑制剂的组合物和方法
WO2016123378A1 (en) 2015-01-30 2016-08-04 Kim Hyungsoo Cancer therapy using jak inhibitor in combination with mapk inhibitors
JP6636031B2 (ja) 2015-01-30 2020-01-29 ジェネンテック, インコーポレイテッド 治療用化合物およびその使用
WO2016126878A2 (en) 2015-02-03 2016-08-11 The Trustees Of The University Of Pennsylvania Listeria-based immunomodulation
CN112494653A (zh) 2015-02-05 2021-03-16 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
WO2016123679A1 (en) 2015-02-06 2016-08-11 Ferrao Petranel Theresa Christine A method of treatment
US20180021259A1 (en) 2015-02-10 2018-01-25 Memorial Sloan Kettering Cancer Center Dye-stabilized nanoparticles and methods of their manufacture and therapeutic use
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2016139534A2 (en) 2015-03-02 2016-09-09 Strand Life Sciences Private Limited Apparatuses and methods for determining a patient's response to multiple cancer drugs
KR20170122799A (ko) 2015-03-02 2017-11-06 리겔 파마슈티칼스, 인크. TGF-β 억제제
MX2017011196A (es) 2015-03-03 2018-05-22 Biohaven Pharm Holding Co Ltd Farmacos precursores de riluzol y sus usos.
EP3265079A4 (en) 2015-03-03 2019-01-02 Caris MPI, Inc. Molecular profiling for cancer
WO2016139331A1 (en) 2015-03-05 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of melanoma
CN107428728A (zh) 2015-03-19 2017-12-01 3-V生物科学股份有限公司 脂质合成的杂环调节剂
RU2015110071A (ru) 2015-03-23 2016-10-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО "ФармТех" Применение новых химических соединений (варианты) в качестве ингибиторов nuak1 киназы для лечения онкологических заболеваний
PL3072529T3 (pl) 2015-03-26 2018-04-30 Ratiopharm Gmbh Kompozycja zawierająca wemurafenib i HPMC-AS
EP3072528B1 (en) 2015-03-26 2017-07-05 ratiopharm GmbH Composition comprising vemurafenib and cationic copolymer based on methacrylates
US20180078561A1 (en) 2015-03-31 2018-03-22 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
JP2016193848A (ja) 2015-03-31 2016-11-17 東レ株式会社 Braf阻害剤耐性メラノーマの治療又は予防剤
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
WO2016160833A1 (en) 2015-04-01 2016-10-06 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
EP3280454A1 (en) 2015-04-07 2018-02-14 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2016168264A1 (en) 2015-04-13 2016-10-20 Kiromic, Llc Methods and compositions for treating cancer with dendritic cells
WO2016168150A2 (en) 2015-04-13 2016-10-20 The Board Of Regents Of The University Of Texas System Treatment for cancer metastasis
CZ2015250A3 (cs) 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
CN108138234A (zh) 2015-04-15 2018-06-08 普罗麦迪奥股份有限公司 治疗骨髓增生性障碍的方法
WO2016168634A1 (en) 2015-04-17 2016-10-20 Bulldog Pharmaceuticals, Inc. Biomarkers related to treatment of cancer with her3 and egfr inhibitors
WO2016168721A1 (en) 2015-04-17 2016-10-20 The Trustees Of The University Of Pennsylvania Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
AU2016252038B2 (en) 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
EP3195865A1 (de) 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Kombinationen von irak4 inhibitoren und btk inhibitoren
KR20160129609A (ko) 2015-04-30 2016-11-09 삼성전자주식회사 Braf 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
WO2016182893A1 (en) 2015-05-08 2016-11-17 Teh Broad Institute Inc. Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
US10568948B2 (en) 2015-05-13 2020-02-25 Agenus Inc. Vaccines for treatment and prevention of cancer
WO2016187122A1 (en) 2015-05-15 2016-11-24 University Of Iowa Research Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
EP3298160B1 (en) 2015-05-20 2020-07-08 PamGene B.V. Method for predicting the response of melanoma patients to targeted pharmacotherapy
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
US9814714B2 (en) 2015-05-22 2017-11-14 Plexxikon Inc. Kinase modulation, and indications therefor
CN114807367A (zh) 2015-05-27 2022-07-29 奎斯特诊断投资股份有限公司 用于筛选实体瘤的组合物和方法
WO2016196384A1 (en) 2015-05-29 2016-12-08 Fred Hutchinson Cancer Research Center Compositions for cellular immunotherapy
WO2016193955A1 (en) 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
CN117257802A (zh) 2015-06-05 2023-12-22 伊利诺伊大学董事会 Pac-1联合疗法
WO2016200688A1 (en) 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
WO2016200778A1 (en) 2015-06-08 2016-12-15 Children's Medical Center Corporation Methods for treatment of melanoma
WO2016200726A1 (en) 2015-06-08 2016-12-15 Texas Tech University System Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors
US20180311251A1 (en) 2015-06-10 2018-11-01 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
CA2988578A1 (en) 2015-06-12 2016-12-15 Indiana University Research & Technology Corporation Predicting suicidality using a combined genomic and clinical risk assessment
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3103450A1 (en) 2015-06-12 2016-12-14 Friedrich-Alexander-Universität Erlangen-Nürnberg None-hydrophobic compounds for use in treating metastasis and/or cartilage defect
AU2015242210A1 (en) 2015-06-15 2017-12-07 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers for conjugation
WO2015151079A2 (en) 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Auristatin analogues and their conjugates with cell-binding molecules
WO2017004153A1 (en) 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
EP4272735A1 (en) 2015-06-30 2023-11-08 Genentech, Inc. Immediate-release tablets containing a drug and processes for forming the tablets
EP3317246A4 (en) 2015-07-04 2019-02-27 Suzhou M-conj Biotech Co., Ltd. SPECIFIC CONJUGATION OF A CELL BINDING MOLECULE
US20180371550A1 (en) 2015-07-08 2018-12-27 Children's Hospital Medical Center Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
EP3319965B1 (en) 2015-07-08 2022-05-04 Biomedical Research Foundation of the Academy of Athens Novel compounds for use in treating or preventing cancerous diseases
FI127517B (sv) 2015-07-10 2018-08-15 Oy El Ho Ab Hydrauliska lösningar hos ett arbetsmaskin
EP3319993B1 (en) 2015-07-10 2020-01-15 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2017019520A1 (en) 2015-07-24 2017-02-02 Memorial Sloan Kettering Cancer Center Compositions and methods of cerenkov targeted and activated imaging and therapeutics
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017019664A1 (en) 2015-07-28 2017-02-02 University Of Iowa Research Foundation Compositions and methods of treating cancer
WO2017021857A1 (en) 2015-07-31 2017-02-09 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and cancer
CN116726183A (zh) 2015-08-03 2023-09-12 Enb治疗公司 用于治疗与etbr激活相关的癌症的组合物和方法
AU2016302344A1 (en) 2015-08-06 2018-03-08 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondrial biogenesis for cancer therapy
WO2017023994A1 (en) 2015-08-06 2017-02-09 Yale University Small molecule based antibody-recruiting compounds for cancer treatment
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
JP6817288B2 (ja) 2015-08-10 2021-01-20 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
WO2017176265A1 (en) 2016-04-06 2017-10-12 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3777978A1 (en) 2015-08-18 2021-02-17 Rakuten Medical, Inc. Phthalocyanine dye conjugates and their storage
AU2016308337B2 (en) 2015-08-18 2019-02-28 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2017031427A1 (en) 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
US20170056327A1 (en) 2015-08-25 2017-03-02 The Methodist Hospital Micro/nano composite drug delivery formulations and uses thereof
US20190060309A1 (en) 2015-08-28 2019-02-28 Novartis Ag Mdm2 inhibitors and combinations thereof
JP6971970B2 (ja) 2015-09-03 2021-11-24 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics, Inc. ペプチド模倣大環状分子およびその使用
US9771363B2 (en) 2015-09-21 2017-09-26 Plexxikon Inc. Heterocyclic compounds and uses thereof
US10016422B2 (en) 2015-09-30 2018-07-10 Oregon State University Nanocarrier drug delivery platform
WO2017059268A1 (en) 2015-10-01 2017-04-06 Mitchell Woods Pharmaceuticals, Inc. Methods of reducing chemoresistance and treating cancer
EP3355923B1 (en) 2015-10-01 2022-02-23 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma
US9724393B2 (en) 2015-10-06 2017-08-08 The Wistar Institute Of Anatomy And Biology Method for treatment of metastatic and refractory cancers and tumors with an inducer that overcomes inhibition of T cell proliferation
WO2017066193A1 (en) 2015-10-15 2017-04-20 Princeton Drug Discovery, Llc Novel inhibitors of protein kinases
US10646576B2 (en) 2015-10-21 2020-05-12 Sprna Gmbh Immunostimulating-toxic RNA in alkaline earth metal formulation
WO2017067592A1 (en) 2015-10-21 2017-04-27 Biontech Ag Cytotoxic immunostimulating particles and uses thereof
CN114404581A (zh) 2015-10-22 2022-04-29 摩登纳特斯有限公司 癌症疫苗
US20170115275A1 (en) 2015-10-23 2017-04-27 Arizona Board Of Regents On Behalf Of Arizona State University Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
CA3004530A1 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2017083788A1 (en) 2015-11-14 2017-05-18 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
WO2017083789A1 (en) 2015-11-14 2017-05-18 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
KR20180081591A (ko) 2015-11-19 2018-07-16 제넨테크, 인크. B-raf 억제제 및 면역 체크포인트 억제제를 사용하여 암을 치료하는 방법
EP3377894B1 (en) 2015-11-20 2019-12-25 Treat4Life AB Method for drug binding analysis in a tissue sample
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
US20180369195A1 (en) 2015-11-30 2018-12-27 The Regents Of The University Of California Combination therapy for treatment of melanoma
WO2017091865A1 (en) 2015-12-03 2017-06-08 Alfred Health Monitoring treatment or progression of myeloma
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
SG11201804711RA (en) 2015-12-07 2018-07-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2017098336A1 (en) 2015-12-11 2017-06-15 Laurus Labs Private Limited Novel polymorphs of vemurafenib, process for its preparation and pharmaceutical composition thereof
WO2017106189A1 (en) 2015-12-14 2017-06-22 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ras/mapk mutant lung cancer
RU2018123481A (ru) 2015-12-16 2020-01-20 Мерк Шарп И Доум Корп. Анти-lag3 антитела и антигенсвязывающие фрагменты
WO2017117182A1 (en) 2015-12-29 2017-07-06 Board Of Regents, The University Of Texas System Inhibition of p38 mapk for the treatment of cancer
WO2017117052A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
WO2017120600A1 (en) 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Compositions and methods of treating wet age-related macular degeneration
WO2017127282A1 (en) 2016-01-19 2017-07-27 The General Hospital Corporation Cancer treatments and methods of selecting same
EP3199641B1 (en) 2016-01-27 2021-09-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Means and methods for staging, typing and treating a cancerous disease
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム,インコーポレイティド 癌を処置するための併用療法
CN107709288A (zh) 2016-02-03 2018-02-16 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
MY197069A (en) 2016-02-04 2023-05-24 Sct Ii Llc Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
CA3013412C (en) 2016-02-04 2023-10-10 Suzhou M-Conj Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
WO2017136741A1 (en) 2016-02-05 2017-08-10 Evol Science LLC Combinations to treat cancer
US20170226518A1 (en) 2016-02-09 2017-08-10 Autotelic Llc Compositions and methods for treating cancer
KR20180103817A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
US11666656B2 (en) 2016-02-24 2023-06-06 Ramot At Tel-Aviv University Ltd. Polymeric conjugates and uses thereof
WO2017145179A1 (en) 2016-02-24 2017-08-31 Indian Institute Of Technology, Bombay Drug delivery system
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
EP3423055A4 (en) 2016-03-01 2019-10-16 Intezyne Technologies Inc. USE OF TRANS- [TETRACHLOROBIS (1H-INDAZOLE) RUTHENATE (III)] FOR THE TREATMENT OF CANCER
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
CN109069511A (zh) 2016-03-10 2018-12-21 鲁特里斯制药有限公司 Braf抑制剂用于治疗皮肤反应的用途
WO2017161045A1 (en) 2016-03-16 2017-09-21 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
WO2017161188A1 (en) 2016-03-16 2017-09-21 The Regents Of The University Of California Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
KR101921676B1 (ko) 2016-03-22 2018-11-26 한국과학기술원 Tesk1 억제제를 포함하는 항암제 내성 억제용 조성물 및 tesk1 억제제의 스크리닝 방법
WO2017162510A1 (en) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Substituted quinazolinone compounds for the treatment of proliferative diseases
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
US20190161523A1 (en) 2016-04-12 2019-05-30 Blaze Bioscience, Inc. Methods of treatment using chlorotoxin conjugates
CA3020854A1 (en) 2016-04-14 2017-10-19 Creatv Microtech, Inc. Methods of using pd-l1 expression in treatment decisions for cancer therapy
WO2017180820A1 (en) 2016-04-15 2017-10-19 The Penn State Research Foundation Compositions and methods for targeted delivery of therapeutic and/or diagnostic agents
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2017181149A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
WO2017184534A1 (en) 2016-04-18 2017-10-26 The Gorlin Companies Methods and compositions for improving safety and efficacy of natural killer cell immunotherapy
ES2886935T3 (es) 2016-04-25 2021-12-21 Forma Therapeutics Inc Inhibidores de FASN para su uso en el tratamiento de esteatohepatitis no alcohólica
US20200397894A1 (en) 2016-04-27 2020-12-24 University Of Virginia Patent Foundation Compositions and methods for treating cancer
JP2019112307A (ja) 2016-04-28 2019-07-11 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物および他の乾癬治療薬が組み合わせて投与される医薬組成物
WO2017193086A1 (en) 2016-05-06 2017-11-09 Tarrex Biopharma Inc. Therapeutic compounds and methods
WO2017196989A1 (en) 2016-05-10 2017-11-16 Unicorn Therapeutics, Llc Compositions of muscle stimulated myokines and methods of use thereof
EP3455753A1 (en) 2016-05-12 2019-03-20 F. Hoffmann-La Roche AG System for predicting efficacy of a target-directed drug to treat a disease
WO2017200826A1 (en) 2016-05-16 2017-11-23 Albert Einstein College Of Medicine, Inc. Assays and compounds for treatment of cancer
JP6103111B1 (ja) 2016-05-24 2017-03-29 三生医薬株式会社 経口医薬組成物及び該組成物からなる粒子状製剤の製造方法
MA45146A (fr) 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc Dérivés de pyrazolopyridine pour le traitement du cancer
JP7160688B2 (ja) 2016-05-24 2022-10-25 ジェネンテック, インコーポレイテッド Cbp/ep300の複素環式インヒビターおよびがんの処置におけるそれらの使用
CA3025486A1 (en) 2016-05-25 2017-11-30 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3463370A4 (en) 2016-05-27 2020-04-08 The Board of Regents of The University of Texas System 6-THIO-2'-DESOXYGUANOSINE (6-THIO-DG) CAUSES TELOMERASE DEPENDENT TELEOMERS AND CELL DEATH IN THERAPY RESISTANT CANCER CELLS
AR108671A1 (es) 2016-06-03 2018-09-12 Enlibrium Inc Análogos de diamida imidodicarbonimidica
WO2017212420A1 (en) 2016-06-07 2017-12-14 Centre For Cellular And Molecular Platforms Methods and compositions for managing neuroinflammation and neurodegeneration
WO2017218365A1 (en) 2016-06-16 2017-12-21 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
DK3471722T3 (da) 2016-06-17 2023-12-04 Univ Pennsylvania Forbindelser, sammensætninger og fremgangsmåder til forebyggelse og/eller behandling af cancer
GB201610628D0 (en) 2016-06-17 2016-08-03 Mihranyan Albert New compositions
TW201805000A (zh) 2016-06-20 2018-02-16 庫拉腫瘤技術股份有限公司 利用erk抑制劑之鱗狀細胞癌之治療
EP3471701A4 (en) 2016-06-21 2020-02-19 The Regents of the University of California Wound healing with the help of Braf inhibitors
US11179484B2 (en) 2016-06-24 2021-11-23 University Of Iowa Research Foundation Compositions and methods of treating melanoma
EP3474849A4 (en) 2016-06-27 2020-07-29 The Broad Institute, Inc. COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF DIABETES
US11207392B2 (en) 2016-06-30 2021-12-28 Nantcell Inc. Coordinated multi-prong cancer therapy
RS60451B1 (sr) 2016-07-01 2020-07-31 Fermion Oy Novi postupci za dobijanje vemurafeniba
WO2018009528A1 (en) 2016-07-05 2018-01-11 Tdw Group Combination cancer immunotherapies with arginine depletion agents
WO2018009904A2 (en) 2016-07-08 2018-01-11 Tumeh Paul C Compositions and treatment methods for cancer immunotherapy
JP2019524713A (ja) 2016-07-08 2019-09-05 ゲンマブ エー/エス 抗axl抗体に基づく抗体薬物コンジュゲートのための新しい投薬レジメン
US10711312B2 (en) 2016-07-12 2020-07-14 The Regents Of The University Of California Methods for immunotherapy-based treatment and assessment of cancer
US20180015075A1 (en) 2016-07-14 2018-01-18 Children's Hospital Medical Center Methods and compositions for treatment of venous malformation
EP3269365A1 (en) 2016-07-14 2018-01-17 Friedrich-Alexander-Universität Erlangen-Nürnberg Kras inhibitor for use in treating cancer
CA2937896A1 (en) 2016-08-02 2018-02-02 Universite De Montreal Use of mubritinib for the treatment of poor prognosis acute myeloid leukemia
WO2018031707A1 (en) 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
AU2017311927B2 (en) 2016-08-16 2021-06-03 National Institute Of Advanced Industrial Science And Technology Malignant tumor target peptide
EP3500686B1 (en) 2016-08-18 2024-01-10 Quest Diagnostics Investments LLC Methods for detecting craniopharyngioma and for selecting medicaments and patients for treatment
DK3506884T3 (da) 2016-08-30 2021-07-26 Dana Farber Cancer Inst Inc Sammensætninger til indgivelse af medicin og anvendelser af disse
MX2019002473A (es) 2016-09-01 2019-09-18 Mayo Found Medical Education & Res Métodos y composiciones para el direccionamiento de cánceres de células t.
KR102462041B1 (ko) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체-pd-l1 결합제 조성물
WO2018049027A1 (en) 2016-09-07 2018-03-15 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and pge2 antagonists
WO2018049250A1 (en) 2016-09-08 2018-03-15 Curematch, Inc. Optimizing therapeutic options in personalized medicine
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ido及tdo調節之化合物及方法以及其適應症
EP3519436A4 (en) 2016-09-30 2020-09-09 Baylor College of Medicine TISSUE-ORIENTED ANTIBODY-BASED GENE THERAPY
WO2018071549A1 (en) 2016-10-11 2018-04-19 New York University Nanoparticles and uses thereof
IL248468A0 (en) 2016-10-13 2017-01-31 Technion Res & Dev Foundation Use of caspase-3 inhibitors and caspase-3 activators in the preparation of medical preparations for cancer treatment and wound healing
WO2018075447A1 (en) 2016-10-19 2018-04-26 The Trustees Of Columbia University In The City Of New York Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
KR20190042775A (ko) 2016-10-19 2019-04-24 사인패스 파마 인코포레이티드 채널병증을 야기하는 약물에 대한 DMPC, DMPG, DMPC/DMPG, LysoPG 및 LysoPC의 보호 효과
US20200078360A1 (en) 2016-11-03 2020-03-12 The Regents Of The University Of Michigan Small molecule dual inhibitors of egfr/pi3k and uses thereof
MX2019005141A (es) 2016-11-09 2019-09-26 Signpath Pharma Inc Efecto protector de dmpc, dmpg, dmpc/dmpg, lisopg y lisopc contra fármacos que causan canalopatías.
KR102459469B1 (ko) 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US11441192B2 (en) 2016-11-15 2022-09-13 Quest Diagnostics Investments Llc Methods for detecting DNA mutations using mitra tip extraction
EP3541400A2 (en) 2016-11-18 2019-09-25 Sanford Burnham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
KR20190077476A (ko) 2016-11-18 2019-07-03 뉴로바이브 파마슈티컬 에이비 상글리페린 거대고리 유사체의 항암 화합물로서의 용도
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
AU2017363257B2 (en) 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
WO2018095353A1 (en) 2016-11-25 2018-05-31 Sunshine Lake Pharma Co., Ltd. Salts of aminoquinazoline derivative and uses thereof
WO2018102769A1 (en) 2016-12-01 2018-06-07 Bluelink Pharmaceuticals, Inc. Treatment of cancer
US11473088B2 (en) 2016-12-02 2022-10-18 Ohio University Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down
US11590133B2 (en) 2016-12-11 2023-02-28 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of BRAF mutant cancers
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
WO2018118611A1 (en) 2016-12-19 2018-06-28 Nantbio, Inc. Methods and artificial tumors for validating an antitumor immune response
HUE055970T2 (hu) 2016-12-20 2022-01-28 Treat4Life Ab Eljárás BRAF mutációk és vad típusú BRAF fehérje meghatározására tömegspektrometria segítségével
CA3045744A1 (en) 2016-12-20 2018-06-28 Eth Zurich Identification of drugs targeting non-genetic drug tolerance programs in cancer
WO2018115888A1 (en) 2016-12-21 2018-06-28 N4 Pharma Uk Limited Novel formulations of aprepitant
BR112019012878A2 (pt) 2016-12-23 2019-11-26 Arvinas Operations Inc compostos e métodos para a degradação alvo de polipeptídos de fibrossarcoma rapidamente acelerados
TW201825087A (zh) 2017-01-05 2018-07-16 杏國新藥股份有限公司 胰臟癌治療
FR3061658A1 (fr) 2017-01-07 2018-07-13 Guy Faustin Monkam Nitcheu Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou du methylhydroxychalcone polymere et/ou du beta-sitosterol et/ou de
WO2018132660A1 (en) 2017-01-13 2018-07-19 University Of Miami Integrator inhibitors and methods for their use
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
TR201702500A2 (tr) 2017-02-20 2017-07-21 Anadolu Ueniversitesi Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
US9861833B1 (en) 2017-03-30 2018-01-09 Norman H. Anderson Methods of treating melanoma

Also Published As

Publication number Publication date
CN110291089A (zh) 2019-09-27
CA3049926A1 (en) 2018-07-26
BR112019014593A2 (pt) 2020-02-18
NZ755835A (en) 2023-12-22
JP2020505452A (ja) 2020-02-20
US20190365723A1 (en) 2019-12-05
JP7300394B2 (ja) 2023-06-29
EP3571200B8 (en) 2022-08-03
ES2928773T3 (es) 2022-11-22
AU2018209164B2 (en) 2021-11-04
AU2018209164A1 (en) 2019-08-15
WO2018134254A1 (en) 2018-07-26
US11040027B2 (en) 2021-06-22
CN110291089B (zh) 2022-05-27
EP3571200A1 (en) 2019-11-27
ZA201905078B (en) 2023-04-26
EP3571200B1 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
MX2019008458A (es) Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos.
MX2020007954A (es) Inhibidores de la proteina cinasa cinasa 4 activada por mitogeno (mkk4) para promover la regeneracion del higado o reducir o prevenir la muerte de los hepatocitos.
JOP20220242A1 (ar) أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3
MX2020014102A (es) Inhibidores de proteina quinasa para promover la regeneracion del higado o reducir o prevenir la muerte de hepatocito.
PH12017501155B1 (en) Thieno [2,3-c] pyrrol-4-one derivatives as erk inhibitors
MX2018001395A (es) Derivados de pirazol pirimidina y sus usos.
PH12018500869A1 (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
TR201911244T4 (tr) İmidazolonilkinolinler ve atm kinaz inhibitörleri olarak kullanımı.
MD4801B1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
MX2022001115A (es) Inhibidores de proteina quinasa de pirazolo-piridina sustituida con heteroarilo para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocito.
CO2017004784A2 (es) Isómeros de ácido-1-[(3-cloro-2-fluoro-fenil)metil]-4-[[3-fluoro-6-[(5-metil-1h-pirazol-3-il)amino]-2-piridil]metil]-2-metil-piperidin-4-carboxílico como inhibidores de la cinasa aurora a
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
WO2016198698A3 (en) P38 inhibitors for the treatment and prophylaxis of liver cancer
TN2017000465A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
WO2016081773A3 (en) Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
MX2017014084A (es) Formulaciones de deposito inyectables.
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
NZ738876A (en) Motile sperm domain containing protein 2 and inflammation
WO2016154329A3 (en) P38 map kinase inhibitors for treating friedreich's ataxia
IL267221B1 (en) Bacillus-based ingredients to inhibit or delay the growth of enterococcus spp. in animals
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
WO2015119575A3 (en) Improved method, combination and/or composition for inducing cardiomyocyte or neuronal differentation
IL279215A (en) Mitogen-activated protein kinase kinase 7 inhibitors
IN2014MU00815A (es)